Cognition Therapeutics Inc (CGTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.03-1.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CGTX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Initiate a Phase 3 registrational study for zervimesine in dementia with Lewy bodies (DLB) psychosis, aligned with FDA feedback, targeting mid-2027 start.
Stated as a priority in 3 of last 3 quarters. Management has consistently communicated plans to initiate a Phase 3 registrational trial for zervimesine in DLB psychosis, with FDA alignment on trial design and an expected start in mid-2027. This trajectory is delivering as the company received FDA feedback confirming psychosis as an approvable outcome and is preparing for trial initiation.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Focused on initiating our Phase 3 study in mid-2027 with an improved tablet composition.”
“FDA agreed psychosis associated with DLB could be an approvable outcome and aligned on pivotal trial design.”
“Filed request to meet FDA Division of Psychiatry to discuss registrational study plans for DLB psychosis.”
Advance clinical development of zervimesine in Alzheimer's disease through the ongoing Phase 2 START study with topline results expected in 2027.
Stated as a priority in 2 of last 3 quarters. Management has maintained focus on the Phase 2 START trial for Alzheimer's disease, with 545 participants and $81M grant funding. Topline results are expected in 2027, consistent with prior disclosures. The program is progressing as planned with no reported delays.
“Phase 2 START trial ongoing with $81M NIA grant funding and data expected in 2H 2027.”
“Topline results from the Phase 2 START study in MCI and early Alzheimer's disease anticipated in 2027.”
Ensure liquidity to support operations and capital expenditures through the second quarter of 2027.
Stated as a priority in 4 of last 5 quarters. The company reported cash and equivalents of $34.8M at 2026-Q2, down slightly from $37.0M at 2025-Q4, with management consistently estimating sufficient cash runway through at least Q2 2027. The trajectory shows stable liquidity supporting operations as planned.
“Company estimates sufficient cash to fund operations and capital expenditures into Q4 2027.”
“Company estimates sufficient cash to fund operations and capital expenditures through Q2 2027.”
“Company estimates sufficient cash to fund operations and capital expenditures into Q2 2027.”
“Company estimates sufficient cash to fund operations and capital expenditures into Q2 2026.”
Control operating expenses and reduce net losses to improve financial sustainability.
Stated as a priority in 3 of last 3 quarters. Management has reduced research and development expenses from $11.5M in 2025-Q2 to $5.1M in 2026-Q2 and improved net loss from $6.7M to $3.9M over the same period. This reflects delivering on cost management and reduced cash burn.
“R&D expenses $5.1M vs. $11.5M prior year; net loss $3.9M vs. $6.7M prior year.”
“R&D expenses $6.1M vs. $10.8M prior year; net loss $4.6M vs. $8.5M prior year.”
“Operating loss $13.7M; net loss $8.5M for full year 2025.”
Over the trailing year it converted 0.93x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
4 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.